Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals Completes $1 Million Financing With Technology Partners

December 27, 2012 • 8:00 AM EST

Tonix Pharmaceuticals Completes Private Placement

December 5, 2012 • 8:36 AM EST

Tonix Pharmaceuticals to Present at Fifth Annual LD Micro Conference

December 5, 2012 • 8:33 AM EST

Tonix Pharmaceuticals Completes Convertible Note Offering

November 14, 2012 • 4:15 PM EST

Tonix Pharmaceuticals Presents Research Findings at the 2012 American College of Rheumatology Annual Scientific Meeting

November 13, 2012 • 8:00 AM EST

TONIX Pharmaceuticals Completes Pre-IND Meeting With FDA for Potential New Treatment for Post-Traumatic Stress Disorder

October 24, 2012 • 8:00 AM EDT

Tonix Pharmaceuticals Confirms Clinical Utility of TNX-102 Sublingual Tablet

October 23, 2012 • 8:00 AM EDT

Tonix Pharmaceuticals to Present at 2012 AEGIS Healthcare Conference

September 24, 2012 • 8:00 AM EDT

Tonix Pharmaceuticals Highlights Therapeutic Programs on CEONEWS.Tv

September 20, 2012 • 8:00 AM EDT

TONIX Pharmaceuticals Announces Poster Presentation at the 2012 American College of Rheumatology Annual Scientific Meeting

September 19, 2012 • 8:38 AM EDT

Show All

News / Press Releases : Press Releases